Chad Winters Biography and Net Worth



Chad R. Winters serves as Chief Accounting Officer, Principal Accounting Officer, Vice President, Controller of the Company. He `was appointed our Vice President and Corporate Controller in October 2019, with responsibility for the accounting, U.S. Securities and Exchange Commission (“SEC”) reporting, and financial operations functions of the Company. He joined the Company from Amneal Pharmaceuticals, Inc., and its predecessors, where he most recently served as Senior Vice President of Finance & Accounting and Controller. Prior to that, Mr. Winters held roles of increasing responsibility at The Chemours Company, UGI Corporation and PricewaterhouseCoopers LLP. Mr. Winters holds a Bachelor of Science degree from Villanova University and is a Certified Public Accountant.

What is Chad Winters' net worth?

The estimated net worth of Chad Winters is at least $466,648.80 as of December 1st, 2023. Mr. Winters owns 1,270 shares of West Pharmaceutical Services stock worth more than $466,649 as of February 26th. This net worth estimate does not reflect any other assets that Mr. Winters may own. Learn More about Chad Winters' net worth.

How old is Chad Winters?

Mr. Winters is currently 45 years old. There are 7 older executives and no younger executives at West Pharmaceutical Services. The oldest executive at West Pharmaceutical Services is Ms. Annette F. Favorite, Chief Human Resources Officer & Senior VP, who is 59 years old. Learn More on Chad Winters' age.

How do I contact Chad Winters?

The corporate mailing address for Mr. Winters and other West Pharmaceutical Services executives is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. West Pharmaceutical Services can also be reached via phone at (610) 594-2900 and via email at [email protected]. Learn More on Chad Winters' contact information.

Has Chad Winters been buying or selling shares of West Pharmaceutical Services?

Chad Winters has not been actively trading shares of West Pharmaceutical Services during the past quarter. Most recently, Chad Winters sold 1,013 shares of the business's stock in a transaction on Friday, December 1st. The shares were sold at an average price of $349.00, for a transaction totalling $353,537.00. Following the completion of the sale, the chief accounting officer now directly owns 1,270 shares of the company's stock, valued at $443,230. Learn More on Chad Winters' trading history.

Who are West Pharmaceutical Services' active insiders?

West Pharmaceutical Services' insider roster includes Silji Abraham (Insider), Bernard Birkett (SVP), Annette Favorite (VP), Eric Green (CEO), Thomas Hofmann (Director), Quintin Lai (VP), George Miller (VP), Cindy Reiss-Clark (Insider), Chad Winters (CAO), and Patrick Zenner (Director). Learn More on West Pharmaceutical Services' active insiders.

Are insiders buying or selling shares of West Pharmaceutical Services?

In the last twelve months, insiders at the medical instruments supplier sold shares 15 times. They sold a total of 173,699 shares worth more than $62,572,781.42. The most recent insider tranaction occured on December, 1st when CAO Chad Winters sold 1,013 shares worth more than $353,537.00. Insiders at West Pharmaceutical Services own 1.1% of the company. Learn More about insider trades at West Pharmaceutical Services.

Information on this page was last updated on 12/1/2023.

Chad Winters Insider Trading History at West Pharmaceutical Services

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/1/2023Sell1,013$349.00$353,537.001,270View SEC Filing Icon  
See Full Table

Chad Winters Buying and Selling Activity at West Pharmaceutical Services

This chart shows Chad Winters's buying and selling at West Pharmaceutical Services by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

West Pharmaceutical Services Company Overview

West Pharmaceutical Services logo
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Read More

Today's Range

Now: $367.44
Low: $360.77
High: $367.97

50 Day Range

MA: $362.82
Low: $338.27
High: $413.00

2 Week Range

Now: $367.44
Low: $306.86
High: $415.73

Volume

488,500 shs

Average Volume

592,846 shs

Market Capitalization

$26.93 billion

P/E Ratio

46.63

Dividend Yield

0.22%

Beta

1.05